Safety of Vinflunine in Patients with Advanced Urothelial Carcinoma Refractory to Platinum-based Chemotherapy: A Prospective Pilot Study
- 1 January 2019
- journal article
- research article
- Published by Bentham Science Publishers Ltd. in Current Drug Safety
- Vol. 14 (1) , 31-36
Abstract
Background: Several single chemotherapeutic agents have been evaluated as the second-line treatment of advanced urothelial carcinoma. Despite encouraging efficacy outcomes, toxicity has often led to dose modifications or discontinuation. We aimed to assess the safety of vinflunine in a particular population of advanced transitional cell carcinoma of urothelium (TCCU), that were exposed to the previous toxicity of chemotherapy. Methods: This is an open-label, prospective, single-center pilot study to evaluate the response rate and safety profile of vinflunine in patients with advanced TCCU. It was planned to enroll 25 evaluable patients. Eligible patients are those with progressive disease after first-line platinum-based regimen for advanced or metastatic disease. Results: The study was prematurely closed due to two sudden deaths that were judged by the review board as treatment-related. Only ten patients were evaluated and received at least one cycle of vinflunine. All but one were male and seven underwent radical surgery. Eight had a distant metastasis (mainly lung and/or liver). Disease control rate was 40%, four patients had a partial response with median duration of response of 3.5 months. The median overall survival was 3.2 months (95% CI: 1.67-4.73). There were three serious adverse events namely two sudden deaths and one grade 4 thrombocytopenia. Nine grade 3/4 adverse events occurred. The most common all-grade adverse events were fatigue (50%), constipation (40%) and vomiting (40%). Moreover, grade 3 fatigue occurred in 30% of patients. Only one patient, who achieved PR for 5 months, was fit to receive further cytotoxic chemotherapy. Conclusion: The activity of vinflunine in advanced urothelial carcinoma came at the expense of its safety. The use of vinflunine has to be limited to the selected group of patients. However, this is a single institute experience in a limited number of patients.Keywords
This publication has 27 references indexed in Scilit:
- The First Slovak Experience with Second-line Vinflunine in Advanced Urothelial CarcinomasKlinicka onkologie, 2014
- Safety and effectiveness of vinflunine in patients with metastatic transitional cell carcinoma of the urothelial tract after failure of one platinum-based systemic therapy in clinical practiceBMC Cancer, 2014
- Monotherapy with Intravenous Vinflunine in Patients with Advanced or Metastatic Urothelial Cancer after Failure of a Platinum-Containing Regimen: A Retrospective Analysis of German Routine DataUrologia Internationalis, 2013
- Combined treatment with pazopanib and vinflunine in patients with advanced urothelial carcinoma refractory after first-line therapyAnti-Cancer Drugs, 2013
- Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapyAnnals of Oncology, 2013
- Phase III Trial of Vinflunine Plus Best Supportive Care Compared With Best Supportive Care Alone After a Platinum-Containing Regimen in Patients With Advanced Transitional Cell Carcinoma of the Urothelial TractJournal of Clinical Oncology, 2009
- Vinflunine in platinum‐pretreated patients with locally advanced or metastatic urothelial carcinomaCancer, 2009
- Efficacy and Safety of Gemcitabine Monotherapy in Patients with Transitional Cell Carcinoma after Cisplatin-Containing Therapy: A Japanese ExperienceJapanese Journal of Clinical Oncology, 2007
- A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimenBritish Journal of Cancer, 2006
- Vinflunine, the latest Vinca alkaloid in clinical developmentCritical Reviews in Oncology/Hematology, 2001